• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Barinthus Biotherapeutics plc

    4/25/25 4:14:15 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BRNS alert in real time by email
    DEFA14A 1 tm2512839d1_defa14a.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

     

    Securities Exchange Act of 1934 (Amendment No.          )

     

     

    Filed by the Registrant              x

     

    Filed by a Party other than the Registrant            ¨

     

    Check the appropriate box:

     

    ¨ Preliminary Proxy Statement
    ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ¨ Definitive Proxy Statement
    x Definitive Additional Materials
    ¨ Soliciting Material under §240.14a-12

     

    BARINTHUS BIOTHERAPEUTICS PLC

    (Name of Registrant as Specified in Its Charter)

     

    N/A

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check all boxes that apply):

     

    x No fee required.
    ¨ Fee paid previously with preliminary materials.
    ¨ Fee computed on table below in exhibit required  by Item 25(b) Exchange Act Rules 14a-6(i)(14) and 0-11.

     

     

    GRAPHIC

    Your Vote Counts! BARINTHUS BIOTHERAPEUTICS PLC 2025 Annual Meeting Vote by June 03, 2025 11 :59 PM ET You invested in BARI NTH US BIOTHERAPEUTICS PLC and it's time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the shareholder meeting to be held on June 10, 2025. Get informed before you vote View the Annual Report on Form 10-K, U.K. Statutory Annual Accounts and Reports, Proxy Statement on line OR you can receive a free paper or email copy of the material(s) by request ing prior to May 19, 2025. If you would like to request a copy of the material(s) for this and/or future shareholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. w For complete information and to vote, visit www.ProxyVote.com Control# ~ [!I r Point your camera here and [!I .. vote without entering a Smartphone users ~!number xxxx xxxx xxxx xxxx Vote in Person at the Meeting* June 10, 2025 9:30 AM EST Goodwin Procter (UK) LLP Sancroft, 10-15 Newgate Street London, EC1A 7AZ 2:30 PM London Time

    GRAPHIC

    Get the next $BRNS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BRNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Hammacher Alex

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    6/11/25 5:18:30 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wright Robin

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    6/11/25 5:17:38 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Morgon Pierre A.

    4 - Barinthus Biotherapeutics plc. (0001828185) (Issuer)

    6/11/25 5:16:31 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    SEC Filings

    View All

    Amendment: Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K/A - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    8/8/25 4:20:09 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Barinthus Biotherapeutics plc

    10-Q - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    8/7/25 8:06:49 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barinthus Biotherapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Barinthus Biotherapeutics plc. (0001828185) (Filer)

    8/7/25 8:05:23 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

    The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD) part of the AVALON trial initiated; Available resources and cash runway guidance into 2027 remains unchanged. GERMANTOWN, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended June 30, 2025, and provided an overview of the Company's c

    8/7/25 8:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

    Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance

    5/7/25 8:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

    Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&

    3/20/25 7:22:19 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    Leadership Updates

    Live Leadership Updates

    View All

    Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

    OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio"), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr. Lynn succeeds Nadège Pelletier, Ph.D. who decided to pursue alternative opportunities closer to home after having served as Barinthus Bio's CSO since early 2023. Barinthus Bio is a clinical-stage biopharmaceutical company developing novel immunotherapeutic candidates that guide T cells to control disease. "Dr. Pelletier's strong vision and leadership have resulted in a robust preclinical pipeline of promising leads for

    11/25/24 4:01:00 PM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

    OXFORD, United Kingdom, May 01, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS), formerly Vaccitech plc, a clinical-stage biopharmaceutical company developing novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer, today announced the appointment of Leon Hooftman, M.D., as Chief Medical Officer (CMO). "We are happy to welcome Dr. Hooftman to Barinthus Bio as our Chief Medical Officer. With his experience spearheading clinical studies from early development through late-stage trials, he is a valuable addition to the Barinthus Bio team during a critical time in our growth," said Chi

    5/1/24 7:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    Financials

    Live finance-specific insights

    View All

    Barinthus Bio Reports Second Quarter 2025 Financial Results and Updates on Corporate Developments

    The final cohort of the single ascending dose (SAD) part of the Phase 1 AVALON trial initiated, with the SAD data readout expected early in the fourth quarter of 2025;The multiple ascending dose (MAD) part of the AVALON trial initiated; Available resources and cash runway guidance into 2027 remains unchanged. GERMANTOWN, Md., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance with curative potential, today announced its financial results for the quarter ended June 30, 2025, and provided an overview of the Company's c

    8/7/25 8:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barinthus Bio Reports First Quarter 2025 Financial Results and Updates on Corporate Developments

    Highly differentiated immunotherapy for celiac disease (VTP-1000) in the clinic, with Phase 1 single ascending dose readout from AVALON expected in the third quarter of 2025;Initiation of VTP-1000 multiple ascending dose expected in the second half of 2025; Encouraging results from HBV003 and IM-PROVE II presented at EASL, supporting ongoing partnering efforts; Available resources expected to provide a cash runway into 2027. OXFORD, United Kingdom and GERMANTOWN, Md., May 07, 2025 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation ("I&I") company focused on developing therapies that promote immune tolerance

    5/7/25 8:00:00 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

    Strategic transformation ongoing, positioning the Company as a focused leader in immunology and inflammatory diseasesHighly differentiated, potentially curative immunotherapy for celiac disease (VTP-1000) in the clinic, with first data expected in third quarter of 2025Proprietary SNAP-TI platform promoting antigen-specific immune tolerance is anticipated to drive multiple future pipeline and partnership opportunities Strategic prioritization of resources expected to provide a cash runway into 2027 OXFORD, United Kingdom and GERMANTOWN, Md., March 20, 2025 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ:BRNS) ("Barinthus Bio," or the "Company"), an immunology and inflammation (I&

    3/20/25 7:22:19 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BRNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Barinthus Biotherapeutics plc

    SC 13G/A - Barinthus Biotherapeutics plc. (0001828185) (Subject)

    11/1/24 11:20:26 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Barinthus Biotherapeutics plc

    SC 13G - Barinthus Biotherapeutics plc. (0001828185) (Subject)

    10/15/24 11:07:21 AM ET
    $BRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care